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Abstract
Background: Ivacaftor acts as a potentiator of the cystic fibrosis transmembrane conductance regulator (CFTR) and
increases the transepithelial chloride transport of CFTR in 9 of 10 known gating mutations causing cystic fibrosis.
S549R is a rare gating mutation considered to be less sensitive to potentiators than all other gating mutations.
Case presentation: We report our first experience with ivacaftor in an 8-year-old boy with the rare S549R gating
mutation. Besides subjective clinical improvements, the sweat chloride level and the lung clearance index
decreased impressively within a few weeks of treatment while forced expiratory volume in the first second values
remained in normal range.
Conclusion: We emphasize the value of measuring small airway function by lung clearance index as an outcome
measure for new interventions targeting the correction of the CFTR defect at an age before traditional lung
function parameters start to deteriorate.
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Background
Ivacaftor acts as a potentiator of the cystic fibrosis trans-
membrane conductance regulator (CFTR) and increases
the transepithelial chloride (Cl−) transport of CFTR in 9
of 10 known gating mutations and in R117H mutation
(class IV) causing cystic fibrosis. Ivacaftor has been ap-
proved in 2012 by the US Food and Drug Administration
(FDA) for G551D, the most common gating mutation,
after improvements in lung function and lowering of
sweat chloride levels had been demonstrated in clinical
trials [1]. In 2014 the approval was extended for 8 add-
itional gating mutations, including S549R. S549R is a rare
gating mutation (41 described patients in CFTR2 [2]) pri-
marily described in the Bedouin population of the United
Arab Emirates, in Saudi Arabia and in North Africa. The
clinical phenotype seen with the homozygous S549R mu-
tation is generally severe and similar to homozygous del-
taF508 mutation [3, 4]. This mutation causes an additional
mild processing defect besides the defective CFTR channel
gating resulting in a lower in vitro response to ivacaftor
than all the other gating mutations [5]. Information on
clinical benefits of ivacaftor in this particularly rare muta-
tion is scarce at present [6].
The measurement of ventilation inhomogeneity, such
as the lung clearance index (LCI), is more sensitive than
forced expiratory volume in the first second (FEV1) to
detect early lung function abnormalities [7–10]. Further,
normal tidal breathing is often easier to perform for
younger children than forced expiratory maneuvers. LCI,
measured by N2 multiple-breath washout (N2MBW),
represents the number of lung volume turnovers re-
quired to clear the lung of N2 to 1/40
th of the starting
concentration [10]. The duration of the test depends on
the degree of ventilation inhomogeneity and can there-
fore be time-consuming in very severe lung disease. We
report our first experience with ivacaftor and the use-
fulness of LCI in a young Swiss patient with the S549R
mutation to demonstrate improvements in lung func-
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An 8-year-old boy with S549R/1717-1G > A genotype
was started on ivacaftor (150 mg b.i.d.) on compassion-
ate use. At the age of 9 months he was diagnosed with
CF due to failure to thrive. His previous history was
remarkable for recurring nasal polyposis requiring endo-
scopic surgery and exocrine pancreatic insufficiency
necessitating enzyme replacement therapy. He grew with
body weight and height along the 10th percentile. He suf-
fered from rather mild respiratory symptoms, primarily
intermittent productive cough, and had close to normal
lung function parameters in previous years as measured by
body plethysmography and spirometry (minimal z-score of
FEV1: −1.2). Sputum cultures grew Haemophilus influenzae
and Staphylococcus aureus on several occasions. After
6 weeks of ivacaftor treatment, the patient reported clinical
improvements in cough frequency, sputum production,
physical performance, and less salt cravings. He gained
1.4 kg in body weight without changing the dose of his
pancreatic enzyme replacement therapy. His sweat
chloride level (Macroduct®) decreased from 115 mmol/l
before ivacaftor to 40 mmol/l after 6 weeks and
52 mmol/l after 41 weeks (normal < 30 mmol/l [11]) of
treatment. His FEV1 increased from 1.25 L (−1.2 z-score)
to 1.65 L (+0.5 z-score) after 41 weeks of ivacaftor therapy.
The LCI (normal < 8) measured by N2-MBW decreased
from 14.5 to 8.3 after 6 weeks and 7.8 after 41 weeks of
ivacaftor treatment (Table 1 and Fig. 1).
Discussion
Ivacaftor is the first authorized drug that improves defect-
ive CFTR function in rare mutations by potentiating the
CFTR channel gating function. In vitro data suggests that
ivacaftor has a similar effect on 9 of 10 CFTR gating mu-
tations. However, the weakest drug effect was described
for the S549R mutation [5]. S549R was initially considered
a class II mutation leading to defective CFTR protein pro-
cessing [12]. Recent electrophysiological studies using
Fischer rat thyroid cells have suggested the presence of a
predominant gating defect besides a mild processing
defect of CFTR in S549R [5]. The processing defect may
account for the lower ivacaftor response observed in vitro.
Against this background, the impressive clinical and func-
tional improvement in our patient with the S549R muta-
tion was better than expected. These results are in line
with a recently published clinical trial study including four
patients with S549R mutation [6].
One limitation of this report is that no nasal potential
differences or intestinal current measurement have been
performed as further functional parameters. The benefit
of using LCI as an outcome measure should not be over
generalised from this case. However this report highlights
the additional value of LCI as a sensitive parameter in
relation to the traditional lung function parameter FEV1.
Other studies have shown that the LCI of N2MBW is
particularly useful in monitoring the early course of lung
disease in young children with CF, particularly in those
with normal spirometry [13, 14]. The LCI is already ele-
vated in presymptomatic or minimally symptomatic
infants and young children with CF [9]. In our patient, the
LCI decreased after 41 weeks of ivacaftor treatment from
a z-score of 14.2 to 1.5, while the z-score for FEV1
remained within the normal range (z-score −1.2 to 0.5).
This is in agreement with previous work indicating that
LCI is a more sensitive parameter to detect treatment
success in young CF patients compared to spirometry, es-
pecially in children with little respiratory symptoms and
near-normal spirometric lung volumes such as FEV1 [15].
Conclusion
This report provides anecdotal evidence of benefit of
ivacafor in S549R mutation.
Further it illustrates the potential value of lung clear-
ance index to serve as an outcome measure for new in-
terventions targeting the correction of the CFTR defect
Table 1 Improvement of functional parameters during ivacaftor
therapy
Start 6 weeks 12 weeks 28 weeks 41 weeks
Sweat chloride level
[mmol/l]
115 40 30 40 52












































Improvement of different functional parameters during 41 weeks of ivacaftor
therapy: FEV1 Forced expiratory volume in the first second, LCI lung clearance
index. aReference population for z-score values of FEV1 are the global multi-
ethnic reference equations of the global lung function initiative [16]. bReference
population for z-score values of the LCI is our intracentric age-matched healthy
control population
Fig. 1 Changes in z-score of LCI and FEV1 during ivacaftor treatment
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at an early stage of the disease. This is relevant since
ivacaftor approval has recently been extended to pre-
school children where performance and interpretation
of spirometry is even more challenging. Such measure-
ments may help to convince medical healthcare payers to
cover the cost of the drug in our young CF population.
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